The focus on mental health has been growing as more research on psychedelic substances and their potential benefits as alternative treatments of various mental health conditions is conducted. Thus far, research has found that psychedelics such as mescaline, LSD and psilocybin mushrooms can help treat mental conditions, including depression, anxiety, addiction and post-traumatic stress disorder.
Attention on this space has also been emphasized by the numerous literary works on the substances that are being published. A new documentary film on psychedelics, titled “Breaking Through,” which was directed and produced by Dan Laughton, a filmmaker based in London, is one of these works. Laughton is a graduate of Ravensbourne University. He’s been building his career by working with various major brands, which include LADbible, the British Army and Reebok.
Laughton’s objective in the creation of documentaries is to produce raw stories that have a cinematic touch and people can resonate with. In an interview with Creative Boom, the director notes that while his work varies from commercial work to documentaries, he follows his passion of exploring different individuals, as well as their stories and what makes them tick. He asserted that his goal was to progress into longer documentaries, revealing that he had many projects and pitches at different stages of development.
The short documentary questions if policymakers were wrong to begin a war on psychedelics as well as investigating the role that psychedelic substances can play with regard to helping those suffering with post-traumatic stress disorder. Post-traumatic stress disorder is a mental health condition characterized by a failure to recover after witnessing or experiencing a terrifying event. The documentary centers on the story Guy Murray, an army veteran who served in the Afghanistan war.
It examines how sessions of psychedelic-assisted therapy assisted him in working through his trauma as well as his feelings of depression that he had sustained during his time in the war. It also looks into how we as a society treat mental health, noting that while the conversation on mental health has gained ground in the recent years, society still has a long way to go.
Currently, one in five individuals in the United Kingdom suffer from trauma, depression and anxiety. The UK is at the foreground of psychedelic-assisted therapy,as advocates and physicians continue to push for more treatments that can be incorporated into psychotherapy.
This film also shows how those who suffer from trauma are stuck in the middle of the decades-long drug war, which has left many experts wondering whether we would have more understanding of psychedelic substances and their use in therapy if the substances were better understood. The full documentary, which is 20 minutes long, can be viewed on Vimeo.
In case you are tempted to think that the contents of this documentary are heavily embellished in true Hollywood style, consider the fact that companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are heavily invested in leveraging psychedelics in order to come up with superior medicines for mental health conditions.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.